Monday, September 24, 2018 7:19:50 PM
First, the long-term trend is up because the stock broke the March highs with a 39% advance from May to August. Second, the 50-day EMA is above the 200-day EMA and price is above both EMAs.
After breaking the red resistance zone in early July, the stock established support in the 360 area over the last few months. Even after a gap down in early August, the stock held this support zone and moved above the early August high. The stock has since corrected with a falling flag of sorts and is edging above the trend line as I write (Monday morning, September 24th).
http://schrts.co/HscMEf
The indicator windows show upside volume increasing over the last few months and the PPO turning up. Note the advance began in mid May with a surge in upside volume and upside volume has largely outpaced downside volume the last four months. The PPO (5,30,5) flattened out just above the zero line and remains just below its signal line. A bullish signal line crossover would confirm the upturn on the price chart.
All my posts are just my opinions. I receive no compensation for
posts. These posts are for entertainment purposes only. I maybe
long or short or hold no position.
Recent REGN News
- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) • GlobeNewswire Inc. • 05/13/2024 05:00:00 AM
- Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks • GlobeNewswire Inc. • 05/08/2024 10:00:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 08:20:02 PM
- Regeneron Announces Investor Conference Presentations • GlobeNewswire Inc. • 05/06/2024 08:05:00 PM
- Regeneron Reports First Quarter 2024 Financial and Operating Results • GlobeNewswire Inc. • 05/02/2024 10:30:00 AM
- EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases • GlobeNewswire Inc. • 04/29/2024 11:00:18 AM
- Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases • GlobeNewswire Inc. • 04/25/2024 11:00:00 AM
- Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO • GlobeNewswire Inc. • 04/24/2024 02:05:18 PM
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) • GlobeNewswire Inc. • 04/22/2024 09:54:01 PM
- Ericsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More News • IH Market News • 04/16/2024 11:18:19 AM
- Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News • IH Market News • 04/11/2024 11:24:54 AM
- Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma • GlobeNewswire Inc. • 04/07/2024 08:00:12 PM
- Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024 • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- Regeneron Provides Update on Biologics License Application for Odronextamab • GlobeNewswire Inc. • 03/25/2024 11:00:02 AM
- High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization • PR Newswire (US) • 03/13/2024 03:55:00 AM
- High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization • GlobeNewswire Inc. • 03/13/2024 01:30:22 AM
- Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol • GlobeNewswire Inc. • 03/11/2024 11:00:23 AM
- EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet • GlobeNewswire Inc. • 03/08/2024 12:00:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:01:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:01:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 09:14:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:04:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:04:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:04:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:34:44 PM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM